Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2019-- Veracyte, Inc. (Nasdaq: VCYT) (“the Company”) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
View HTML
Toggle Summary Veracyte Announces First Quarter 2019 Financial Results
Grew Revenue by 47% to $29.5 Million Grew Genomic Test Volume by 33% to 9,162 Tests Company Raises 2019 Annual Revenue Guidance Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State
Novel Genomic Test Helps Improve Diagnosis of Idiopathic Pulmonary Fibrosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has received regulatory authorization from the New York State
View HTML
Toggle Summary Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Alfred “Freddie” Bowie, Jr., Ph.D., as vice president, corporate and business development. In this role, Dr.
View HTML
Toggle Summary Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype
RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 8, 2019-- Veracyte, Inc . announced today that a new study published online in BMC Systems
View HTML
Toggle Summary Veracyte to Release First Quarter 2019 Financial Results on April 30, 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019 . Company management will host a conference call and webcast to
View HTML
Toggle Summary Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF
Novel genomic test distinguishes IPF from other lung-scarring diseases without the need for surgery SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Veracyte, Inc . announced that data published online today in The Lancet Respiratory Medicine suggest that use of the company’s Envisia
View HTML
Toggle Summary Veracyte Announces Participation in the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 18 th Annual Needham Healthcare Conference in New York
View HTML
Toggle Summary Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer
Findings Presented at ENDO 2019 Conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 25, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with
View HTML
Toggle Summary Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition
Support Reinforces Company’s Commitment to Tackling This Deadly Disease SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomics diagnostics company, today announced its “Summit” level sponsorship of the Climb to Fight Cancer’s Team
View HTML